Correlation between high CCL3 levels (> 10 pg/mL) and established prognostics markers in CLL
| Characteristic . | Category . | Frequency, % . | P . |
|---|---|---|---|
| Sex | Female | 44.9 | .1886 |
| Male | 52.6 | ||
| RAI stage | 0 | 31.5 | < .0001 |
| I | 39.9 | ||
| II | 63.0 | ||
| III | 84.6 | ||
| IV | 75.6 | ||
| IgVH | Mutated | 28.9 | < .0001 |
| Unmutated | 72.9 | ||
| CD38 | Negative | 41.7 | < .0001 |
| Positive | 75.0 | ||
| ZAP-70 | Negative | 35.3 | < .0001 |
| Positive | 69.9 | ||
| β2-microglobulin | < 4 mg/L | 37.8 | < .0001 |
| ≥ 4 mg/L | 86.2 | ||
| Cytogenetics | del 13q | 34.8 | < .0001 |
| Diploid | 52.8 | ||
| Trisomy 12q | 69.4 | ||
| del 11q | 71.1 | ||
| del 17p | 71.0 | ||
| CCL4, pg/mL | High (≥ 60) | 74.3 | < .0001 |
| Low (< 60) | 26.3 |
| Characteristic . | Category . | Frequency, % . | P . |
|---|---|---|---|
| Sex | Female | 44.9 | .1886 |
| Male | 52.6 | ||
| RAI stage | 0 | 31.5 | < .0001 |
| I | 39.9 | ||
| II | 63.0 | ||
| III | 84.6 | ||
| IV | 75.6 | ||
| IgVH | Mutated | 28.9 | < .0001 |
| Unmutated | 72.9 | ||
| CD38 | Negative | 41.7 | < .0001 |
| Positive | 75.0 | ||
| ZAP-70 | Negative | 35.3 | < .0001 |
| Positive | 69.9 | ||
| β2-microglobulin | < 4 mg/L | 37.8 | < .0001 |
| ≥ 4 mg/L | 86.2 | ||
| Cytogenetics | del 13q | 34.8 | < .0001 |
| Diploid | 52.8 | ||
| Trisomy 12q | 69.4 | ||
| del 11q | 71.1 | ||
| del 17p | 71.0 | ||
| CCL4, pg/mL | High (≥ 60) | 74.3 | < .0001 |
| Low (< 60) | 26.3 |
CCL3 was significantly associated (P < .0001) with death, advanced clinical stages, IgVH mutation status, CD38, ZAL-70, β2-microglobulin, high-risk cytogenetic subgroups, and CCL4.